MX2022005882A - Combinaciones de 1-(((2s,3s,4s)-3-etil-4-fluoro-5-oxopirrolidin-2- il)metoxi)-7-metoxiisoquinolin-6-carboxamida y formas de dosis orales. - Google Patents
Combinaciones de 1-(((2s,3s,4s)-3-etil-4-fluoro-5-oxopirrolidin-2- il)metoxi)-7-metoxiisoquinolin-6-carboxamida y formas de dosis orales.Info
- Publication number
- MX2022005882A MX2022005882A MX2022005882A MX2022005882A MX2022005882A MX 2022005882 A MX2022005882 A MX 2022005882A MX 2022005882 A MX2022005882 A MX 2022005882A MX 2022005882 A MX2022005882 A MX 2022005882A MX 2022005882 A MX2022005882 A MX 2022005882A
- Authority
- MX
- Mexico
- Prior art keywords
- methoxyisoquinoline
- oxopyrrolidin
- carboxamide
- fluoro
- methoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere al descubrimiento de nuevas formulaciones de dosis oral y tratamientos conjuntos para 1-(((2S,3S,4S)-3-etil-4-fluoro-5-oxopirrolidin-2-il)metoxi)-7-met oxiisoquinolin-6-carboxamida, o una sal aceptable desde el punto de vista farmacéutico de esta, para tratar afecciones mejoradas mediante la inhibición de IRAK4.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962935450P | 2019-11-14 | 2019-11-14 | |
US202063024174P | 2020-05-13 | 2020-05-13 | |
PCT/IB2020/060627 WO2021094953A1 (en) | 2019-11-14 | 2020-11-11 | 1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022005882A true MX2022005882A (es) | 2022-06-14 |
Family
ID=73476209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022005882A MX2022005882A (es) | 2019-11-14 | 2020-11-11 | Combinaciones de 1-(((2s,3s,4s)-3-etil-4-fluoro-5-oxopirrolidin-2- il)metoxi)-7-metoxiisoquinolin-6-carboxamida y formas de dosis orales. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220378707A1 (es) |
EP (1) | EP4057989A1 (es) |
JP (1) | JP2021091663A (es) |
KR (1) | KR20220101150A (es) |
CN (1) | CN114727950A (es) |
AU (1) | AU2020385054B2 (es) |
BR (1) | BR112022007826A2 (es) |
CA (1) | CA3161153A1 (es) |
IL (1) | IL292925A (es) |
MX (1) | MX2022005882A (es) |
TW (1) | TW202128163A (es) |
WO (1) | WO2021094953A1 (es) |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2322793A (en) | 1939-08-21 | 1943-06-29 | Robert S Drummond | Gear finishing tool |
US3247066A (en) | 1962-09-12 | 1966-04-19 | Parke Davis & Co | Controlled release dosage form containing water-swellable beadlet |
US3952741A (en) | 1975-01-09 | 1976-04-27 | Bend Research Inc. | Controlled release delivery system by an osmotic bursting mechanism |
US4519801A (en) | 1982-07-12 | 1985-05-28 | Alza Corporation | Osmotic device with wall comprising cellulose ether and permeability enhancer |
US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
IL91398A (en) | 1988-08-30 | 1994-05-30 | Pfizer | A device for the controlled release of pneumatic substances, including the active substance, surrounded by an asymmetric membrane |
US5358502A (en) | 1993-02-25 | 1994-10-25 | Pfizer Inc | PH-triggered osmotic bursting delivery devices |
PL218519B1 (pl) | 1999-12-10 | 2014-12-31 | Pfizer Prod Inc | Związki pirolo [2,3-d] pirymidynowe, środek farmaceutyczny zawierający te związki oraz ich zastosowanie |
US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
WO2005053652A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
BRPI0416535A (pt) | 2003-12-04 | 2007-01-09 | Pfizer Prod Inc | processo de congelamento por vaporização empregando um extrusor para preparar composições de azitromicina de multiparticulado contendo preferivelmente um poloxámero e um glicerìdeo |
CA2547597A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate compositions with improved stability |
US20080199527A1 (en) | 2004-12-21 | 2008-08-21 | Pfizer Inc. | Enteric Coated Azithromycin Multiparticulates |
BRPI0710914A2 (pt) | 2006-04-24 | 2011-09-27 | Pfizer Prod Inc | forma de dosagem e método para o tratamento de dependência, adição e supressão de nicotina, em particular para uso na terapia para parar de fumar |
JP6041823B2 (ja) * | 2013-03-16 | 2016-12-14 | ファイザー・インク | トファシチニブの経口持続放出剤形 |
CN107417684A (zh) | 2013-12-05 | 2017-12-01 | 辉瑞公司 | 杂环丙烯酰胺 |
MD4779B1 (ro) | 2014-04-04 | 2021-12-31 | Pfizer Inc. | Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4 |
PL3341367T3 (pl) * | 2015-08-27 | 2021-07-12 | Pfizer Inc. | Skondensowane bicyklicznie związki heteroarylowe lub arylowe jako modulatory IRAK4 |
US20170035881A1 (en) * | 2015-10-19 | 2017-02-09 | Acerta Pharma B.V. | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor |
-
2020
- 2020-11-11 MX MX2022005882A patent/MX2022005882A/es unknown
- 2020-11-11 WO PCT/IB2020/060627 patent/WO2021094953A1/en unknown
- 2020-11-11 EP EP20808525.8A patent/EP4057989A1/en active Pending
- 2020-11-11 IL IL292925A patent/IL292925A/en unknown
- 2020-11-11 KR KR1020227019982A patent/KR20220101150A/ko unknown
- 2020-11-11 AU AU2020385054A patent/AU2020385054B2/en active Active
- 2020-11-11 CA CA3161153A patent/CA3161153A1/en active Pending
- 2020-11-11 CN CN202080079704.6A patent/CN114727950A/zh active Pending
- 2020-11-11 US US17/755,601 patent/US20220378707A1/en active Pending
- 2020-11-11 BR BR112022007826A patent/BR112022007826A2/pt unknown
- 2020-11-13 TW TW109139675A patent/TW202128163A/zh unknown
- 2020-11-13 JP JP2020189237A patent/JP2021091663A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4057989A1 (en) | 2022-09-21 |
BR112022007826A2 (pt) | 2022-07-05 |
AU2020385054B2 (en) | 2023-10-12 |
IL292925A (en) | 2022-07-01 |
JP2021091663A (ja) | 2021-06-17 |
TW202128163A (zh) | 2021-08-01 |
CN114727950A (zh) | 2022-07-08 |
CA3161153A1 (en) | 2021-05-20 |
WO2021094953A1 (en) | 2021-05-20 |
US20220378707A1 (en) | 2022-12-01 |
KR20220101150A (ko) | 2022-07-19 |
AU2020385054A1 (en) | 2022-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551821A1 (en) | Novel compounds | |
CR20220258A (es) | Inhibidores de kras g12c | |
MX2021016085A (es) | Derivados de benzisoxazol sulfonamida. | |
AR108711A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
MX2023010411A (es) | Inhibidores de erbb/btk. | |
MX2023005099A (es) | Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central. | |
EA032928B1 (ru) | Бициклические кетосульфонамидные соединения | |
MX2021015854A (es) | Composiciones y métodos para tratar trastornos del snc. | |
MX2023008954A (es) | Inhibidores de los receptores erbb. | |
MX2022006783A (es) | Nuevos derivados de metilquinazolinona. | |
PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
EA202193015A1 (ru) | Ингибиторы cdk | |
MX2019006843A (es) | Inhibidor de cdk4/6. | |
EA200601194A1 (ru) | Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором | |
PH12021550554A1 (en) | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors | |
WO2021079196A3 (en) | Mettl3 modulators | |
SA521431279B1 (ar) | D1 مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي | |
MX2022004197A (es) | Inhibidores del factor d del complemento para administracion oral. | |
MX2021012105A (es) | Compuestos de pirrol. | |
MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
MX2021015942A (es) | Composiciones y métodos para tratar trastornos del snc. | |
PH12020500542A1 (en) | Dopamine-b-hydroxylase inhibitors | |
MX2022005882A (es) | Combinaciones de 1-(((2s,3s,4s)-3-etil-4-fluoro-5-oxopirrolidin-2- il)metoxi)-7-metoxiisoquinolin-6-carboxamida y formas de dosis orales. | |
WO2022115381A8 (en) | Compositions and methods for treating cns disorders | |
MX2022012881A (es) | Inhibidores de replicacion del virus de inmunodeficiencia humana. |